Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06308926 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients

Name: MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients — clinical trial record (NCT06308926)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SUMMIT

StatusUnknown

PhasePhase 2

SponsorMedRegen LLC

Started2024-12-01

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 23, 2024 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.

This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.

Amendment history 1 change detected by DataLookout

2026-09-06

Trial status changed: Not Yet Recruiting → Unknown

Trial Details

NCT Number	NCT06308926
Lead Sponsor	MedRegen LLC Collaborators: Vanderbilt University Medical Center
Conditions	Acute Respiratory Distress Syndrome, Respiratory Failure, Respiratory Distress Syndrome, Respiratory Tract Diseases, Cytokine Storm
Enrollment	60 participants
Start Date	2024-12-01
Primary Completion	2026-02-01 (estimated)
Study Completion	2026-07-01 (estimated)
Updated on ClinicalTrials.gov	2024-08-23